Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript February 28, 2025
Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.53 EPS, expectations were $-0.44.
Chris Gibson: Welcome everybody to Recursion’s Earnings Call. I’m Chris Gibson, Co-Founder and CEO, and I’m excited to take you through Recursions 2024, 2025 and the time ahead. So with that we’ll jump into the slides and I want to just set the stage first of all to share a...
